In a proof-of-principle study, Ohio State University researchers compared the nanopore sequencing assay to short-read sequencing and capillary electrophoresis.
The team will present the results to the US Food and Drug Administration as part of a 510(k) application in order to commercialize the technology with Biofluidica.
Researchers demonstrated the importance of integrating mutational and transcriptomic profiles to improve understanding of AML and MDS patients' prognosis.
Researchers compared single-cell transcriptomic and epigenetic profiles of healthy blood cells and leukemia samples to find a role for RUNX1 in disease.
The firm, a spin-out of Barts Cancer Institute, is developing a mass spec-based test for identifying AML patients likely to respond to the drug midostaurin.
The company's SpliceCore platform maps patient RNA sequencing data to a collection of over 5 million alternative splicing errors to pinpoint ones that cause disease.
